Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD at 4–6 months of t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res
Hlavní autoři: Nazha, Aziz, Sekeres, Mikkael A., Garcia-Manero, Guillermo, Barnard, John, Al Ali, Najla H., Roboz, Gail J., Steensma, David P., DeZern, Amy E., Zimmerman, Cassie, Jabbour, Elias J., Zell, Katrina, List, Alan F., Kantarjian, Hagop M., Maciejewski, Jaroslaw P., Komrokji, Rami S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986515/
https://ncbi.nlm.nih.gov/pubmed/26777537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.12.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky